World's Best Scientists 2026 revealed!
Robert A. Lazarus

Robert A. Lazarus

D-Index & Metrics

Biology and Biochemistry

D-Index
51
Citations
7895
World Ranking
17315
National Ranking
7120

Overview

Robert A. Lazarus is affiliated with Genentech in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with contributions also noted in subfields such as Immunology, Physiology, Pulmonary and Respiratory Medicine, Genetics, and Molecular Biology.

Their work addresses several main topics, including:

  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Asthma and respiratory diseases
  • Mast cells and histamine
  • Cystic Fibrosis Research Advances
  • Monoclonal and Polyclonal Antibodies Research
  • Immune Cell Function and Interaction
  • Receptor Mechanisms and Signaling

Among Lazarus's frequent coauthors are:

  • Henry R. Maun
  • Tangsheng Yi
  • James T. Koerber
  • Janet Jackman
  • Rajesh Vij

They have published in a variety of scientific venues, including:

  • Nature Communications
  • Science Translational Medicine
  • Journal of Allergy and Clinical Immunology
  • Cell
  • Expert Review of Respiratory Medicine

Some of their recent publications include:

  • "Bivalent antibody pliers inhibit β-tryptase by an allosteric mechanism dependent on the IgG hinge," 2020, Nature Communications
  • "Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis," 2022, Science Translational Medicine
  • "An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma," 2020, Cell
  • "Genome-wide association study identifies kallikrein 5 in type 2 inflammation-low asthma," 2022, Journal of Allergy and Clinical Immunology
  • "The continuing need for dornase alfa for extracellular airway DNA hydrolysis in the era of CFTR modulators," 2024, Expert Review of Respiratory Medicine

Best Publications

  • Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors.

    Mark S. Dennis;William J. Henzel;Robert M. Pitti;Michael T. Lipari

  • Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist

    Marc Adler;Robert A. Lazarus;Mark S. Dennis;Gerhard Wagner

  • Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor

    Jennifer Stamos;Robert A Lazarus;Xiaoyi Yao;Daniel Kirchhofer

  • Peptide exosite inhibitors of factor VIIa as anticoagulants

    Mark S. Dennis;Charles Eigenbrot;Nicholas J. Skelton;Mark H. Ultsch

  • A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo

    Jasvinder K. Atwal;Yongmei Chen;Cecilia Chiu;Deborah L. Mortensen

  • Production of 2-Keto-L-Gulonate, an Intermediate in L-Ascorbate Synthesis, by a Genetically Modified Erwinia herbicola

    Stephen Anderson;Cara Berman Marks;Robert Lazarus;Jeffrey Miller

  • Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

    Mark Merchant;Xiaolei Ma;Henry R. Maun;Zhong Zheng

  • Interactions between Hedgehog proteins and their binding partners come into view.

    Philip A. Beachy;Sarah G. Hymowitz;Robert A. Lazarus;Daniel J. Leahy

  • Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display.

    M S Dennis;R A Lazarus

  • Structure of the RGD protein decorsin: conserved motif and distinct function in leech proteins that affect blood clotting.

    Andrzej M. Krezel;Gerhard Wagner;Jana Seymour-Ulmer;Robert A. Lazarus

  • Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.

    Daniel Kirchhofer;Mark Peek;Wei Li;Jennifer Stamos

  • Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site.

    Henry R. Maun;Xiaohui Wen;Andreas Lingel;Frederic J. de Sauvage

  • The structure of SHH in complex with HHIP reveals a recognition role for the Shh pseudo active site in signaling.

    Ivan Bosanac;Henry R Maun;Suzie J Scales;Xiaohui Wen

  • Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins.

    Robert S. McDowell;Mark S. Dennis;Andrea Louie;Michael Shuster

  • Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism

    Mark Merchant;Felix F. Vajdos;Mark Ultsch;Henry R. Maun;Henry R. Maun

  • Ornatins: potent glycoprotein IIb-IIIa antagonists and platelet aggregation inhibitors from the leech Placobdella ornata.

    Paul Mazur;William J. Henzel;Jana L. Seymour;Robert A. Lazarus

  • Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor β-Chain in Met Binding and Signaling

    Daniel Kirchhofer;Xiaoyi Yao;Mark Peek;Charles Eigenbrot

  • Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding.

    Robert F. Kelley;Kimberly E. Costas;Mark P. O'Connell;Robert A. Lazarus

  • Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection.

    M S Dennis;R A Lazarus

  • The factor VII zymogen structure reveals reregistration of beta strands during activation.

    Charles Eigenbrot;Daniel Kirchhofer;Mark S. Dennis;Lydia Santell

Frequent Co-Authors

Stephen J. Benkovic
Stephen J. Benkovic Pennsylvania State University
Ryan J. Watts
Ryan J. Watts Denali Therapeutics (United States)
Christian Wiesmann
Christian Wiesmann Novartis (Switzerland)
Mark Ultsch
Mark Ultsch Genentech

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Robert A. Lazarus

Trending Scientists